A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Conditions

• Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Eligibility Criteria

Sex

ALL

Age

41 Years - 81 Years

Healthy Volunteers

Not accepted

Interventions

• NIO752 — OTHER
  Solution of antisense oligonucleotide.
• Placebo — DRUG
  Placebo solution

Study Details

This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.

Key Dates

Start date

May 29, 2026

Status verified

May 2026

Primary completion

Jul 20, 2029

Completion

Jul 18, 2031

Study Design

Enrollment

300 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: NIO752
  NIO752 solution
• Placebo Comparator: Placebo
  Placebo in solution

Primary Outcome Measure

Change from baseline in the mPSPRS-10 score [ Time Frame: Baseline, Week 72 ]

Central Contacts

• Novartis Pharmaceuticals
  1-888-669-6682
  [email protected]
• Novartis Pharmaceuticals
  +41613241111

Locations (2)

Find similar trials in Englewood, CO